Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01559454 · ClinicalTrials.gov registry record · Phase 4
Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
A Phase 4 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT01559454: Completed Phase 4 study, sponsored by State University of New York at Buffalo.
NCT01559454 is a Phase 4 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01559454, a Phase 4 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
Chronic pain patients are treated with prescription opioids and many exhibit opioid addiction. Currently, there are no evidence-based guidelines to better manage patients with chronic pain and coexistent opioid addiction. This study compares 6-months buprenorphine and methadone treatment in these patients. The investigators hypothesize that both buprenorphine and methadone treatment will reduce pain and addiction behaviors and increase functioning in these patients.
Primary Outcome
Pain severity will be measured using the Visual Analogue Scale (VAS) which has a range of 0-100 with 0 being no pain and 100 being worse possible pain.
Interventions
- DRUG Methadone
- DRUG Buprenorphine/naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
What the finished NCT01559454 record still lists
NCT01559454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Methadone is the first listed.
NCT01559454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01559454 about?
NCT01559454 is a clinical study titled "Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients". Chronic pain patients are treated with prescription opioids and many exhibit opioid addiction. Currently, there are no evidence-based guidelines to better manage patients with chronic pain and coexistent opioid addiction. This study compares 6-months buprenorphine and methadone treatment in these pa...
What is the current status of trial NCT01559454?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2012-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01559454?
The interventions under investigation include: Methadone (DRUG), Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT01559454?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01559454's enrollment target sits among peer trials
19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia